User profiles for Joel R. Lexchin

Joel Lexchin

Professor Emeritus, School of Health Policy & Management, York University
Verified email at yorku.ca
Cited by 17877

Pharmaceutical research and development: what do we get for all that money?

DW Light, JR Lexchin - Bmj, 2012 - bmj.com
Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real
innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that …

Pharmaceuticals as a market for “lemons”: Theory and practice

DW Light, JR Lexchin - Social Science & Medicine, 2021 - Elsevier
Drawing on economic theory and institutional analysis, this paper reframes Akerlof's theory
of how a market for lemons operates and argues that each of the many markets for lemons …

Implications of pharmaceutical industry funding on clinical research

JR Lexchin - Annals of Pharmacotherapy, 2005 - journals.sagepub.com
This commentary explores the influence of industry funding and offers suggestions for
overcoming some of the problems. First, it is difficult to obtain funding from some sources for …

The need to systematically evaluate clinical practice guidelines

…, L Cosgrove, JR Lexchin - The Journal of the …, 2016 - Am Board Family Med
Clinical practice guidelines abound. The recommendations contained in these guidelines
are used not only to make decisions about the care of individual patients but also as practice …

Conflicts of interest and the presence of methodologists on guideline development panels: a cross-sectional study of clinical practice guidelines for major depressive …

…, AF Shaughnessy, SM Peters, JR Lexchin… - Psychotherapy and …, 2017 - karger.com
Guidelines in many disease categories are increasingly recommending drugs as first-line
interventions for mild or subthreshold conditions, raising concerns about the quality and …

[HTML][HTML] Can reporting of adverse drug reactions create safer systems while improving health data?

C Hohl, JR Lexchin, E Balka - CMAJ, 2015 - Can Med Assoc
Existing systems further deterred clinicians from documenting adverse drug reactions because
the systems failed to reflect the clinical processes through which adverse drug reactions …

[PDF][PDF] Cost-of-living challenges highlight urgency for clinicians to prescribe affordable medications

I Gorfinkel, JR Lexchin - Canadian Family Physician, 2023 - cfp.ca
Iris Gorfinkel MDCM Joel R. Lexchin MD CCFP (EM) FCFP More than half of prescribers in
the United States use real-time prescription benefit (RTPB) technology as an add-on to …

[PDF][PDF] From caveat emptor to caveat venditor: time to stop the influence of money on practice guideline development

…, DJ Freeman‐Coppadge, JR Lexchin - Journal of Evaluation …, 2014 - openexcellence.org
Many proponents of evidence-based medicine (EBM) call for the universal implementation
of clinical practice guidelines (CPGs). The assumption is that CPGs are trustworthy and valid, …

Industry involvement in clinical practice guidelines

JR Lexchin - Canadian Family Physician, 2021 - cfp.ca
Family Physician is important and we offer some comments from the United Kingdom. The
beneficial outcomes associated with continuity of family physician care are even stronger than …

Engaging physicians to prescribe more cost-effectively: Blueprint for change

I Gorfinkel, A Brown, JR Lexchin - Canadian Family Physician, 2020 - cfp.ca
$ symbols indicated to physicians the cost category of the antibiotic they were prescribing.
Additionally, a link was provided to a list of antibiotics and their relative costs. The cost …